Vanguard Portfolio Management LLC filed an amended beneficial ownership statement with the SEC on October 30, 2026, disclosing a 4.43% stake in Krystal Biotech Inc as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Vanguard Portfolio Management reported holding 1,312,431 shares of Krystal Biotech Inc common stock, representing 4.43% of the class.
  • Sole dispositive power: Vanguard Portfolio Management holds sole power to dispose of all 1,312,431 shares reported.
  • Sole voting power: Only 25,577 shares carry sole voting power; shared voting power is reported as zero.
  • Triggering date: The event requiring this filing occurred on September 30, 2026.
  • Amendment: This is Amendment No. 1 to a previously filed statement.
  • Affiliated entities included: The filing covers securities held across Vanguard Portfolio Management LLC, Vanguard Fiduciary Trust Company, and Vanguard Global Advisers, LLC.

Vanguard's Reported Position in Krystal Biotech Common Stock

According to the filing, Vanguard Portfolio Management LLC, organized in Pennsylvania and headquartered at 100 Vanguard Blvd, Malvern, PA, disclosed aggregate beneficial ownership of 1,312,431 shares of common stock in Krystal Biotech Inc (NASDAQ:KRYS), a biopharmaceutical company headquartered at 2100 Wharton Street, Suite 701, Pittsburgh, PA. The stake constitutes 4.43% of the class, keeping the position below the 5% threshold, which is explicitly noted in Item 5 of the filing.

The filing states that the reported shares reflect securities held by Vanguard funds, or sleeves thereof, over which Vanguard Portfolio Management LLC exercises dispositive power, as well as securities held by clients over which affiliates including Vanguard Fiduciary Trust Company and Vanguard Global Advisers, LLC exercise dispositive and voting power. The filing further states that it does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Portfolio Management LLC whose ownership is disaggregated from that of the reporting business unit, in accordance with SEC Release No. 34-39538 dated January 12, 1998.

Vanguard Portfolio Management is classified as an investment adviser (type "IA") in the filing. The certification included in the document states that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The filing was signed by My Trieu-Gatt, identified as Authorized Signatory, Head of Global Fund Administration, on October 30, 2026.

What Was Disclosed

Vanguard Portfolio Management LLC filed an amended ownership statement covering 1,312,431 shares of Krystal Biotech Inc common stock, equal to 4.43% of the class, with a triggering event date of September 30, 2026, and sole dispositive power over all reported shares.